Nicolas Bazan
New Targets in Inflammation
Inhibitors of Cox-2 or Adhesion Molecules
Herausgeber: Bazan, N.; Vane, John R; Botting, Jack H
Nicolas Bazan
New Targets in Inflammation
Inhibitors of Cox-2 or Adhesion Molecules
Herausgeber: Bazan, N.; Vane, John R; Botting, Jack H
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This volume contains the proceedings of the William Harvey Research Conference held in New Orleans on the 15th and 16th of April 1996. It reviews the general pathophysiological significance of the isoforms of cyclooxygenase and the likely value of selective COX-2 inhibitors in the treatment of rheumatoid conditions. The volume also covers the possible use of antibodies against cytokines and cell adhesion receptors in the treatment of inflammatory conditions.
Andere Kunden interessierten sich auch für
- K.D. Rainsford (ed.) / G.P VeloNew Developments in Anti-Rheumatic Drugs109,99 €
- Membrane Transporters as Drug Targets157,99 €
- Emerging Drugs and Targets for Alzheimer's Disease: Complete Set318,99 €
- Luis M BotanaTherapeutic Targets191,99 €
- Universita Di VeronaSide-Effects of Anti-Inflammatory Drugs201,99 €
- K.D. Rainsford (ed.)Azapropazone - 20 Years of Clinical Use109,99 €
- New Targets in Inflammation77,99 €
-
-
-
This volume contains the proceedings of the William Harvey Research Conference held in New Orleans on the 15th and 16th of April 1996. It reviews the general pathophysiological significance of the isoforms of cyclooxygenase and the likely value of selective COX-2 inhibitors in the treatment of rheumatoid conditions. The volume also covers the possible use of antibodies against cytokines and cell adhesion receptors in the treatment of inflammatory conditions.
Produktdetails
- Produktdetails
- Verlag: Palgrave MacMillan UK
- Seitenzahl: 164
- Erscheinungstermin: 31. Dezember 1996
- Englisch
- Abmessung: 241mm x 160mm x 15mm
- Gewicht: 418g
- ISBN-13: 9780792387145
- ISBN-10: 0792387147
- Artikelnr.: 24464900
- Verlag: Palgrave MacMillan UK
- Seitenzahl: 164
- Erscheinungstermin: 31. Dezember 1996
- Englisch
- Abmessung: 241mm x 160mm x 15mm
- Gewicht: 418g
- ISBN-13: 9780792387145
- ISBN-10: 0792387147
- Artikelnr.: 24464900
Jack Botting is Consultant at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK. Sir John Vane is the Director General at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK. Sir John Vane shared the Nobel Prize in Physiology or Medicine in 1982 for his discoveries of the mechanism of action of aspirin and of prostacyclin, as well as his work on other prostanoids.
Preface. 1. The History of Anti
Inflammatory Drugs and Their Mechanism of Action; J.R. Vane, R.M. Botting. 2. Structure of Prostaglandin H2 synthase
1 (COX
1) and its NSAID Binding Sites; P.J. Loll. 3. Differential Inhibition of Cyclooxygenases 1 and 2 by NSAIDs; M. Pairet, et al. 4. Blockade of Inflammatory Hyperalgesia and Cyclooxygenase
2; S.H. Ferreira. 5. Brain COX
2 in Experimental Models of Epilepsy and Stroke: Signalling Pathways Leading to Enhanced Expression; N.G. Bazan, et al. 6. New Highly Selective Cyclooxygenase
2 Inhibitors; A.W. Ford
Hutchinson. 7. Characteristics of Cyclooxygenase
1 and Cyclooxygenase
2
Deficient Mice; S.G. Morham, R. Langenbach. 8. X
Ray Crystal Structure of Human Cyclooxygenase
2; M. Browner. 9. Risk of Gastrointestinal Side Effects Caused by Non
Steroid Anti
Inflammatory Drugs (NSAIDs); H. Jick. 10. Expression and Regulation of Cyclooxygenase
2 in Synovial Tissues of Arthritic Patients; L.J. Crofford. 11. Differential Target Tissue Presentation and COX
1/COX
2 Inhibition by Non
Steroid Anti
Inflammatory Drugs: A Rationale for a New Classification; H. Fenner. 12. Clinical Experience with Meloxicam, a Selective COX
2 Inhibitor; W. Bolten. 13. Enzymatic Regulation of the Prostaglandin Response in a Human Model of Inflammation; B.F. Adam, G.A. Fitzgerald. 14. Cyclooxygenase
2 and Intestinal Cancer; R.N. DuBois, et al. 15. Cytokines and Adhesion Molecules in the Lung Inflammatory Response; P.A. Ward. 16. Adhesion Molecules as Targets for Therapy in Rheumatoid Arthritis; P.E. Lipsky, et al. Index.
Inflammatory Drugs and Their Mechanism of Action; J.R. Vane, R.M. Botting. 2. Structure of Prostaglandin H2 synthase
1 (COX
1) and its NSAID Binding Sites; P.J. Loll. 3. Differential Inhibition of Cyclooxygenases 1 and 2 by NSAIDs; M. Pairet, et al. 4. Blockade of Inflammatory Hyperalgesia and Cyclooxygenase
2; S.H. Ferreira. 5. Brain COX
2 in Experimental Models of Epilepsy and Stroke: Signalling Pathways Leading to Enhanced Expression; N.G. Bazan, et al. 6. New Highly Selective Cyclooxygenase
2 Inhibitors; A.W. Ford
Hutchinson. 7. Characteristics of Cyclooxygenase
1 and Cyclooxygenase
2
Deficient Mice; S.G. Morham, R. Langenbach. 8. X
Ray Crystal Structure of Human Cyclooxygenase
2; M. Browner. 9. Risk of Gastrointestinal Side Effects Caused by Non
Steroid Anti
Inflammatory Drugs (NSAIDs); H. Jick. 10. Expression and Regulation of Cyclooxygenase
2 in Synovial Tissues of Arthritic Patients; L.J. Crofford. 11. Differential Target Tissue Presentation and COX
1/COX
2 Inhibition by Non
Steroid Anti
Inflammatory Drugs: A Rationale for a New Classification; H. Fenner. 12. Clinical Experience with Meloxicam, a Selective COX
2 Inhibitor; W. Bolten. 13. Enzymatic Regulation of the Prostaglandin Response in a Human Model of Inflammation; B.F. Adam, G.A. Fitzgerald. 14. Cyclooxygenase
2 and Intestinal Cancer; R.N. DuBois, et al. 15. Cytokines and Adhesion Molecules in the Lung Inflammatory Response; P.A. Ward. 16. Adhesion Molecules as Targets for Therapy in Rheumatoid Arthritis; P.E. Lipsky, et al. Index.
Preface. 1. The History of Anti
Inflammatory Drugs and Their Mechanism of Action; J.R. Vane, R.M. Botting. 2. Structure of Prostaglandin H2 synthase
1 (COX
1) and its NSAID Binding Sites; P.J. Loll. 3. Differential Inhibition of Cyclooxygenases 1 and 2 by NSAIDs; M. Pairet, et al. 4. Blockade of Inflammatory Hyperalgesia and Cyclooxygenase
2; S.H. Ferreira. 5. Brain COX
2 in Experimental Models of Epilepsy and Stroke: Signalling Pathways Leading to Enhanced Expression; N.G. Bazan, et al. 6. New Highly Selective Cyclooxygenase
2 Inhibitors; A.W. Ford
Hutchinson. 7. Characteristics of Cyclooxygenase
1 and Cyclooxygenase
2
Deficient Mice; S.G. Morham, R. Langenbach. 8. X
Ray Crystal Structure of Human Cyclooxygenase
2; M. Browner. 9. Risk of Gastrointestinal Side Effects Caused by Non
Steroid Anti
Inflammatory Drugs (NSAIDs); H. Jick. 10. Expression and Regulation of Cyclooxygenase
2 in Synovial Tissues of Arthritic Patients; L.J. Crofford. 11. Differential Target Tissue Presentation and COX
1/COX
2 Inhibition by Non
Steroid Anti
Inflammatory Drugs: A Rationale for a New Classification; H. Fenner. 12. Clinical Experience with Meloxicam, a Selective COX
2 Inhibitor; W. Bolten. 13. Enzymatic Regulation of the Prostaglandin Response in a Human Model of Inflammation; B.F. Adam, G.A. Fitzgerald. 14. Cyclooxygenase
2 and Intestinal Cancer; R.N. DuBois, et al. 15. Cytokines and Adhesion Molecules in the Lung Inflammatory Response; P.A. Ward. 16. Adhesion Molecules as Targets for Therapy in Rheumatoid Arthritis; P.E. Lipsky, et al. Index.
Inflammatory Drugs and Their Mechanism of Action; J.R. Vane, R.M. Botting. 2. Structure of Prostaglandin H2 synthase
1 (COX
1) and its NSAID Binding Sites; P.J. Loll. 3. Differential Inhibition of Cyclooxygenases 1 and 2 by NSAIDs; M. Pairet, et al. 4. Blockade of Inflammatory Hyperalgesia and Cyclooxygenase
2; S.H. Ferreira. 5. Brain COX
2 in Experimental Models of Epilepsy and Stroke: Signalling Pathways Leading to Enhanced Expression; N.G. Bazan, et al. 6. New Highly Selective Cyclooxygenase
2 Inhibitors; A.W. Ford
Hutchinson. 7. Characteristics of Cyclooxygenase
1 and Cyclooxygenase
2
Deficient Mice; S.G. Morham, R. Langenbach. 8. X
Ray Crystal Structure of Human Cyclooxygenase
2; M. Browner. 9. Risk of Gastrointestinal Side Effects Caused by Non
Steroid Anti
Inflammatory Drugs (NSAIDs); H. Jick. 10. Expression and Regulation of Cyclooxygenase
2 in Synovial Tissues of Arthritic Patients; L.J. Crofford. 11. Differential Target Tissue Presentation and COX
1/COX
2 Inhibition by Non
Steroid Anti
Inflammatory Drugs: A Rationale for a New Classification; H. Fenner. 12. Clinical Experience with Meloxicam, a Selective COX
2 Inhibitor; W. Bolten. 13. Enzymatic Regulation of the Prostaglandin Response in a Human Model of Inflammation; B.F. Adam, G.A. Fitzgerald. 14. Cyclooxygenase
2 and Intestinal Cancer; R.N. DuBois, et al. 15. Cytokines and Adhesion Molecules in the Lung Inflammatory Response; P.A. Ward. 16. Adhesion Molecules as Targets for Therapy in Rheumatoid Arthritis; P.E. Lipsky, et al. Index.